Breitz H B, Sullivan K, Nelp W B
Department of Radiology, University of Washington, Seattle.
Semin Nucl Med. 1993 Apr;23(2):127-32. doi: 10.1016/s0001-2998(05)80093-5.
Radiolabeled antibodies have been studied by several investigators as to their potential role in the diagnosis and staging of lung cancer. Studies with indium-111-labeled antibodies in limited numbers of patients have shown that 75% to 100% of primary lung tumors can be delineated and that the detection of metastases is dependent on size and location. Hepatic metastases and lesions smaller than 2 cm frequently are not visualized. Other studies with a technetium-99m-labeled Fab fragment of NR-LU-10 have been carried out for the staging of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). In a large, well controlled multicenter study of patients with SCLC, staging by antibody imaging alone was as accurate as a combination of the conventional staging tests, and the positive predictive value for antibody staging of extensive disease was greater than 95%. In patients with NSCLC, antibody imaging was comparable to computed tomography for staging the mediastinum and was able to identify distant metastases at the same time.
几位研究者对放射性标记抗体在肺癌诊断和分期中的潜在作用进行了研究。对少数患者使用铟 - 111标记抗体的研究表明，75%至100%的原发性肺肿瘤能够被勾勒出来，并且转移灶的检测取决于其大小和位置。肝转移灶以及小于2厘米的病灶常常无法显影。针对小细胞肺癌（SCLC）和非小细胞肺癌（NSCLC）的分期，还开展了其他使用锝 - 99m标记的NR - LU - 10 Fab片段的研究。在一项针对SCLC患者的大型、严格对照的多中心研究中，仅通过抗体成像进行分期与传统分期检查相结合一样准确，对于广泛期疾病的抗体分期，其阳性预测值大于95%。在NSCLC患者中，抗体成像在纵隔分期方面与计算机断层扫描相当，并且能够同时识别远处转移灶。
